Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3277511A vaccine in COPD patients with prior exacerbations
2017-000880-34Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in chronic obstructive pulmonary disease (COPD) comparing GSK3277511A with Placebo (2 arms). Primary endpoint: Rate of moderate and severe acute exacerbations of COPD. Started Jul 2017; status: completed.
02
Drugs
GSK3277511A
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2017-000880-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000880-34.